PF-08634404

TrialFetch AI summary: Open-label single-arm study for adults with previously untreated transformed SCLC arising after EGFR-mutated NSCLC treated with an EGFR TKI, requiring measurable disease and ECOG 0–1. Participants receive PF-08634404/SSGJ-707, an investigational bispecific antibody targeting PD-1 and VEGF, with chemotherapy followed by PF-08634404 maintenance.

ClinicalTrials.gov ID: NCT07476287

TrialFetch AI summary: Adults with treatment-naïve locally advanced unresectable or metastatic RCC, ECOG 0–1, measurable disease, and any IMDC risk group receive IV PF-08634404 as monotherapy or combined with one of two unspecified anticancer agents. PF-08634404/SSGJ-707 is an investigational bispecific antibody targeting PD-1 and VEGF, intended to combine checkpoint blockade with anti-angiogenic activity.

ClinicalTrials.gov ID: NCT07227415

TrialFetch AI summary: Enrolling adults with ECOG 0–1, measurable locally advanced or metastatic urothelial carcinoma, including previously treated patients and previously untreated first-line patients. Participants receive PF-08634404/SSGJ-707, an investigational bispecific antibody targeting PD-1 and VEGF, either as monotherapy after prior therapy or combined with enfortumab vedotin, a nectin-4–directed antibody-drug conjugate, in the first-line setting.

ClinicalTrials.gov ID: NCT07421700

TrialFetch AI summary: Enrolls treatment-naïve adults with locally advanced or metastatic HER2-negative, PD-L1–positive gastric, gastroesophageal junction, or esophageal adenocarcinoma and ECOG 0–1. Patients receive PF-08634404/SSGJ-707, an investigational bispecific antibody targeting PD-1 and VEGF, plus chemotherapy, with phase 3 comparison against nivolumab plus chemotherapy.

ClinicalTrials.gov ID: NCT07392892

TrialFetch AI summary: Open-label study for adults with previously untreated locally advanced unresectable or metastatic squamous or nonsquamous NSCLC without actionable driver alterations, ECOG 0–1, measurable disease, and available PD-L1 status; Part B requires PD-L1 TPS ≥1%. Patients receive IV PF-08634404, an investigational bispecific PD-1/VEGF antibody, in combination with another anticancer agent, including sigvotatug vedotin, an integrin β6–directed MMAE antibody-drug conjugate, in one cohort.

ClinicalTrials.gov ID: NCT07227298

TrialFetch AI summary: Adults with unresectable stage IIIB/IIIC or metastatic stage IV squamous or non-squamous NSCLC without actionable driver alterations, systemic-therapy naïve for advanced disease (ECOG 0–1, measurable disease, known PD-L1 status), are randomized to PF-08634404/SSGJ-707 (investigational bispecific antibody targeting PD-1 and VEGF) plus histology-appropriate platinum-based chemotherapy followed by maintenance, versus pembrolizumab plus the same chemotherapy followed by standard maintenance. Primary outcomes compare overall survival and centrally reviewed PFS between regimens.

ClinicalTrials.gov ID: NCT07222566

TrialFetch AI summary: Enrolls adults with previously untreated metastatic (stage IV) colorectal adenocarcinoma, ECOG 0–1, RECIST-measurable disease, adequate organ function, excluding MSI-high/dMMR or BRAF V600E tumors and patients with active symptomatic CNS metastases, significant bleeding/cardiovascular risk, or active autoimmune disease requiring systemic therapy. Compares PF-08634404 (SSGJ-707), a bispecific antibody targeting PD-1 and VEGF, plus standard first-line IV chemotherapy versus bevacizumab (anti-VEGF) plus the same chemotherapy, treating until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT07222800

TrialFetch AI summary: Enrolling adults with treatment-naïve extensive-stage small cell lung cancer (ECOG 0–1) and measurable disease, allowing prior curative-intent therapy for limited-stage SCLC if completed ≥6 months earlier, and excluding active CNS metastases/leptomeningeal disease and significant bleeding/fistula risk. Patients receive IV PF-08634404/SSGJ-707 (bispecific anti–PD-1/anti-VEGF antibody combining checkpoint inhibition with anti-angiogenic blockade) plus platinum/etoposide with possible maintenance, compared with atezolizumab plus the same chemotherapy backbone.

ClinicalTrials.gov ID: NCT07226999

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic HCC, Child-Pugh A, ECOG 0–1, and no prior systemic therapy receive PF-08634404/SSGJ-707, an IV bispecific antibody targeting PD-1 and VEGF, either alone or with ipilimumab. The study evaluates dose/safety and preliminary efficacy of PF-08634404 plus CTLA-4 blockade versus PF-08634404 monotherapy in the first-line setting.

ClinicalTrials.gov ID: NCT07227012